Novo Nordisk Sues 2 Pharmacies for Allegedly Selling Adulterated Weight-Loss Drugs

Published on December 1, 2023

Danish pharmaceutical company Novo Nordisk is pursuing legal action against two U.S.-based pharmacies for allegedly selling products claiming to contain semaglutide that are not approved by the U.S. Food and Drug Administration (FDA). In a statement on Nov. 30, the drugmaker said it had conducted tests on compounded products allegedly sold by Wells Pharmacy and Brooksville Pharmaceuticals, two compounding pharmacies based in Florida. The company indicated test results revealed the drugs were “adulterated and misbranded injectable compounded drugs” that claim to contain semaglutide—which is the main ingredient used in Novo Nordisk’s in-demand weight-loss drugs Wegovy and Ozempic....